Recombinant Human CXCL2
| Code | Size | Price |
|---|
| LEI-G131-10ug | 10 ug | £398.00 |
Quantity:
| LEI-G131-50ug | 50 ug | £933.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Human
Regulatory Status: RUO
Shipping:
Ambient
Storage:
This lyophilized protein is stable for six to twelve months when stored desiccated at -20°C to -70°C. After aseptic reconstitution this protein may be stored at 2°C to 8°C for one month or at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. See Product Insert for exact lot specific storage instructions.
Further Information
Format:
This recombinant protein was lyophilized from a 0.2 um filtered solution in 35% acetonitrile (CH3CN) and 0.1% trifluoroacetic acid (TFA).
Formulation:
This recombinant protein was lyophilized from a 0.2 um filtered solution in 35% acetonitrile (CH3CN) and 0.1% trifluoroacetic acid (TFA).
Long Description:
Chemokine (C-X-C motif) ligand 2 (CXCL2), also known as MIP2-α and GROβ, is a small, inducible cytokine belonging to the CXC chemokine family. Other chemokines in this group include IL-8, GROα, GROγ, mouse KC, ENA78, GCP2 and PBP/CTAPIII/β TG/NAP2. Since it is structurally related to IL-8, CXCL2 competes with IL-8 for binding to IL-8 receptors on neutrophils and to a lesser extent, basophils. CXCL2 is involved in attraction of polymorphonuclear granulocytes to sites of infection (1). It is active against Gram-negative (Escherichia coli) and Gram-positive (Staphyllococcus aureus) bacteria. It is secreted by monocytes and macrophages and is chemotactic for hematopoietic stem cells (2-4). MMP-12 cleaves CXCL2 at the ELR sequence motif, which is known to be the critical receptor binding motif leading to the loss of chemotactic activity (5).
NCBI Gene:
2920
Purity:
>97% by SDS-PAGE and analyzed by silver stain.
Target:
CXCL2
References
1. Beuscher, HU. et al. (2004) International Immunol. 16: 1675
2. Cerami, A. et al. (1989) Proc Nat Acad Sci. 86: 612
3. Grotendorst, GR. et al. (1990) Mol Cell Biol. 10: 5596
4. Fukuda, S. et al. (2006) Exp Hematol. 34: 1010
Related Products
| Product Name | Product Code | Supplier | Anti-Rat CXCL2 (Clone 123802) | LEI-C1433 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-Rat Chemokine Ligand 2 | LEI-C1465 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Rat Chemokine (C-X-C Motif) Ligand 2 (CXCL2) - Biotin | LEI-C1509 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Rat CINC-3/CXCL2 ELISA Development Kit | LEI-C1609 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Rat CXCL2 | LEI-G122 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Human GROβ/CXCL2 (aa 39-107) | LEI-G706 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Mouse CXCL2 (Clone 40605) | LEI-M1277 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Mouse CXCL2 | LEI-M178 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Mouse CXCL2-Biotin | LEI-M195 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||